**Core Concept**
The question is testing the student's knowledge on targeted therapy for HER2-positive breast cancer, a subtype of breast cancer characterized by overexpression of the human epidermal growth factor receptor 2 (HER2) protein. HER2-positive breast cancers are more aggressive and have a poorer prognosis than HER2-negative breast cancers.

**Why the Correct Answer is Right**
Trastuzumab, a monoclonal antibody, specifically targets the HER2 protein on the surface of cancer cells. By binding to HER2, trastuzumab interferes with the growth and spread of cancer cells. Trastuzumab also works by inducing antibody-dependent cellular cytotoxicity (ADCC) and inhibiting the HER2/HER3 signaling pathway. This results in reduced tumor growth and prolonged survival in patients with HER2-positive breast cancer.

**Why Each Wrong Option is Incorrect**
**Option A:** While docetaxel is a chemotherapy medication used to treat breast cancer, it is not specifically targeted to HER2-positive breast cancer.
**Option B:** Letrozole is an aromatase inhibitor used to treat hormone receptor-positive breast cancer, not HER2-positive breast cancer.
**Option C:** Paclitaxel is a chemotherapy medication used to treat various types of cancer, including breast cancer, but it is not specifically targeted to HER2-positive breast cancer.

**Clinical Pearl / High-Yield Fact**
Trastuzumab is often used in combination with chemotherapy and other targeted therapies to improve outcomes in patients with HER2-positive breast cancer. It is essential to identify HER2 status in breast cancer patients to determine the most effective treatment strategy.

**Correct Answer: C. Trastuzumab**